Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers

• Published in: Disease markers Vol. 2020; no. 2020; pp. 1 - 21
• Main Authors: Berezin, Alexander E., Berezin, Alexander A.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Adrenomedullin; Atherosclerosis; Biological markers; Biomarkers; Biomechanics; Blood flow; C-reactive protein; Cardiac arrhythmia; Cardiac patients; Cardiovascular diseases; Clinical outcomes; Complications; Coronary artery; Diabetes; Diagnostic systems; Ejection fraction; Fibrosis; Health risks; Heart attack; Heart attacks; Heart failure; Hypertension; Ischemia; Medical prognosis; Mortality; Myocardial infarction; Necrosis; New technology; Pathogenesis; Peptides; Prevention; Prognosis; Review; Risk analysis; Risk factors; Stenosis; Stents; Thrombosis; Tomography; Transluminal angioplasty; Utilities; Veins & arteries
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2020/1215802

The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Numerous studies have examined the diagnostic and prognostic potencies of circulating cardiac biomarkers in acute coronary syndrome/AMI and heart failure after AMI, and even fewer have depicted the utility of biomarkers in AMI patients undergoing primary PCI. Although complete revascularization at early period of acute coronary syndrome/AMI is an established factor for improved short-term and long-term prognosis and lowered risk of cardiovascular (CV) complications, late adverse cardiac remodelling may be a major risk factor for one-year mortality and postponded heart failure manifestation after PCI with subsequent blood flow resolving in culprit coronary artery. The aim of the review was to focus an attention on circulating biomarker as a promising tool to stratify AMI patients at high risk of poor cardiac recovery and developing HF after successful PCI. The main consideration affects biomarkers of inflammation, biomechanical myocardial stress, cardiac injury and necrosis, fibrosis, endothelial dysfunction, and vascular reparation. Clinical utilities and predictive modalities of natriuretic peptides, cardiac troponins, galectin 3, soluble suppressor tumorogenicity-2, high-sensitive C-reactive protein, growth differential factor-15, midregional proadrenomedullin, noncoding RNAs, and other biomarkers for adverse cardiac remodelling are discussed in the review.